vantuylen

Scientists develop all-in-one approach that ‘kicks and kills’ HIV

[From Gay Star News,  April 05 , 2019] “Scientists have developed an all-in-one immunotherapy approach in a bid to ‘cure’ HIV. University of Pittsburgh researchers say they have developed a way to ‘kick’ HIV cells hiding in the immune system. And not only does it kick it out of hiding, the approach also kills it.” For […]

Scientists develop all-in-one approach that ‘kicks and kills’ HIV Read More »

Raltegravir plus lamivudine is likely to work as PrEP

[From aidsmap,  April 05 , 2019] “A combination of the drugs raltegravir and lamivudine produced acceptable drug levels in both women and men, in rectal and vaginal tissues, suggesting that the two drugs could provide an effective alternative to tenofovir-based pre-exposure prophylaxis (PrEP), the 25th Annual Conference of the British HIV Association (BHIVA) heard in Bournemouth yesterday.”

Raltegravir plus lamivudine is likely to work as PrEP Read More »

Inside Grindr, fears that China wanted to access user data via HIV research

[From NBC,  April 02 , 2019] “Just a few months after a Chinese gaming company acquired Grindr, a gay dating app, employees of the app learned that the Trump administration was investigating the deal over national security concerns, according to two people familiar with the company.” For more, click here.

Inside Grindr, fears that China wanted to access user data via HIV research Read More »

Preventing and Responding to HIV Drug Resistance in the African Region: Regional action plan 2019-2023

[From ReliefWeb,  April 04 , 2019] “Global action to combat HIV/AIDS has had an immense impact in the African Region. By the end of 2017, 15.3 million people living with HIV (PLHIV) in the African Region were accessing life-saving antiretroviral drugs (ARVs), representing 70% of the 21.7 million people accessing antiretrovirals (ARV) globally.” For more, click

Preventing and Responding to HIV Drug Resistance in the African Region: Regional action plan 2019-2023 Read More »

Scroll to Top